<p>BridgeBio Oncology Therapeutics Inc. has awarded a new inducement grant to an employee hired in November 2025. The grant consists of non-qualified stock options to purchase 53,060 shares of BBOT common stock at an exercise price of $12.88 per share, the closing price on the grant’s effective date. The options will vest 25% on the first anniversary of the employee’s start date, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on continued employment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9600961-en) on December 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

BBIO

<p>BridgeBio Oncology Therapeutics Inc. has granted stock options to a new employee under an inducement plan. The options allow the purchase of 53,060 shares at $12.88 each, vesting over four years. This announcement was made via GlobeNewswire on December 11, 2025.</p>

BridgeBio Oncology Therapeutics Grants Stock Options Under New Inducement Plan